INTERVIEW: Cook MyoSite Eyes Japan As Cell Therapy Trials Progress
This article was originally published in PharmAsia News
In the wake of supportive regulations introduced in 2014, more and more firms in the regenerative medicines space are eyeing Japan as an attractive market. US-based Cook MyoSite is no exception.
Register for our free email digests: